Vol. 25 No. 9

home / publications / oncology-live / vol-25-no-9

DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment

Kyle Doherty

July 23rd 2024

ArticleClinical Perspectives

Paolo Tarantino MD, and V. K. Gadi, MD, PhD discuss data from DESTINY-Breast03 and DESTINY-Breast06.

340B Drug Pricing Program Ostensibly Improves Cancer Care but Carries Unforeseen Consequences

Kyle Doherty

July 22nd 2024

ArticleOncology Business Management

Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers

Megan Hollasch

July 16th 2024

ArticleConference Highlights

This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.

Suresh S. Ramalingam, MD, FACP, FASCO, of Winship Cancer Institute

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Kyle Doherty

July 12th 2024

ArticleCover Story

As the lung cancer paradigm continues to advance, increasingly effective therapies are under development for previously underserved disease subtypes.

Vivek Subbiah, MD, chief, early-phase drug development, Sarah Cannon Research Institute

Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies

Megan Hollasch

July 11th 2024

ArticlePathways

Recent studies of novel mTOR inhibitors in combination with various agents have shown how these combinations may be used for patients with solid tumors.